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Introduction 
TYRO protein tyrosine kinase-binding protein (TYROBP) (also known as DAP12) is a gene 
located on the long arm of chromosome 19. It encodes a 113 amino acid long 
transmembrane protein that is expressed on macrophages, monocytes, lymphocytes, 
osteoclasts, and, in brain, on microglia (Tomasello and Vivier, 2005). TYROBP plays 
different potential roles including signal transduction, bone modelling, brain myelination, and 
inflammation (Kuroda et al., 2007). TYROBP is a key regulator of the microglia network 
activated in late-onset Alzheimer’s disease (LOAD) and has been shown to be significantly 
upregulated in the brains of Alzheimer’s disease (AD) patients (Frank et al., 2008; Zhang et 
al., 2013). Mutations in TYROBP and TREM2, following an autosomal recessive pattern of 
inheritance, are known to cause Nasu-Hakola disease (Paloneva et al. 2000; Paloneva et al. 
2002). Recently, we and others have identified homozygous and compound heterozygous 
variants in TREM2 as the cause of frontotemporal dementia (FTD) syndromes without 
associated bone phenotypes (Guerreiro et al., 2013a; Guerreiro et al., 2013c) and 
heterozygous rare variants in the same gene as associated with a significant increase in the 
risk of AD (Guerreiro et al., 2013b; Jonsson et al., 2013). 
The close association of TREM2 and TYROBP to the different dementias and the functional 
interaction between them provide support for looking at TYROBP variation in a cohort of 
dementia patients. 
 
Materials and Methods 
	   
Patient cohort	  
All participants were recruited consecutively over 24 months (2010 - 2012) in the Behavioral 
Neurology and Movement Disorders Unit outpatient clinic in Istanbul Faculty of Medicine, 
Istanbul University. They underwent detailed clinical and neuropsychological examination 
and, in most cases, cerebral magnetic resonance imaging (cMRI) or positron emission 
tomography (PET) imaging. The diagnosis of dementia was based on the National Institute 
of Neurological and Communicative Disorders and Stroke and Alzheimer’s disease 
(McKhann et al., 1984). FTD was defined following the criteria of International Behavioural 
Variant FTD Criteria Consortium (Rascovsky et al., 2011) and the criteria developed by an 
international group of PPA investigators (Gorno-Tempini et al., 2011). The diagnosis of 
dementia with Lewy bodies (DLB) was made based on the consensus guidelines from the 
DLB consortium (McKeith, 2006). Diagnostic procedures for Parkinson’s disease dementia 
(PDD) followed the recommendations of the movement disorder society task force (Dubois 
et al., 2007). Twenty cases were diagnosed with mild cognitive impairment (MCI). MCI is 
known to not be a clinically stable entity, with some cases not having an underlying 
neurodegenerative process. Consequently, and given that no clinical follow up was 
performed, it is possible that some of these patients may have improved, some may have 
stabilized and some may have progressed to dementia. 	  
All patients were negative for mutations in known dementia genes: APP, PSEN1, PSEN2, 
NOTCH3, TREM2, MAPT, GRN, C9orf72, CHMP2B, FUS, TARDBP, SQSTM1 and VCP 
(Lohmann et al., 2012; Guerreiro et al., 2012; Guerreiro et al., 2013a; Guven et al., 2016).	  
The study was approved by the Ethics Committee of Istanbul Faculty of Medicine, Istanbul 
University and informed consent was obtained from the patients.      
 
DNA extraction 
Peripheral blood samples were collected and genomic DNA was extracted by standard 
procedures using the Qiagen DNA isolation maxi kit (Qiagen, Hilden, Germany). 
	   
Whole-Genome Genotyping (WGG) 
One hundred and three samples underwent WGG using Illumina Infinium Technology to 
identify the presence of any large structural variants (>50 Kb) and large regions of 
homozygosity (>1 Mb). Samples were run on HumanOmniExpress BeadChips as per the 
manufacturer’s instructions and data were visualized using the GenomeStudio Data Analysis 
Software (Illumina Inc.). The TYROBP locus (chr19:35234335-37547219, based on hg19) 
was analysed, which included two SNPs, rs1802029 and rs3817624, within the TYROBP 
gene (Figure S1).	  
 
Whole-Exome Sequencing (WES)	  
Sixty-four samples underwent whole-exome sequencing. SeqCap EZ Exome Library version 
1.0 (Roche NimbleGen) was used, as per manufacturer’s protocol, to enrich sequences 
corresponding to all annotated human exons by hybridization. One flow cell lane was used to 
sequence each DNA sample, on paired-end 50-base pair HiSeq 2000 runs (Illumina Inc), 
yielding an average of 6 billion high quality bases per sample. Illumina pipeline (version 
1.7.1) was used to perform base calling and image analysis with default parameters. The 
Burrows-Wheeler aligner (Li and Durbin, 2009) was used to map sequence reads to the 
reference genome (GRCh37/hg19) and SAMtools was used to generate BAM files (li et al., 
2009). SNPs and indels were called using the Genome Analysis Toolkit (DePristo et al., 
2011) and annotated with SNPEff (Cingolani et al., 2012). 
 
Sanger Sequencing 
The 5 exons of TYROBP were Sanger sequenced in 39 samples. Exons were amplified by 
polymerase chain reaction (PCR) with Roche FastStart PCR Master Mix (Roche Diagnostics 
Corp) and sequenced with Applied Biosystems BigDye terminator version3.1 sequencing 
chemistry in an ABI3730XL genetic analyzer as per the manufacturer’s instructions (Applied 
Biosystems). Primers are available upon request. The sequences were analysed using 
	  Sequencher software version 4.2 (Gene Codes). The same procedures were used to obtain 
data for exons with low coverage in WES (different exons in 32 samples with average exonic 
coverage below 8x).	  
 
In silico analysis 
Minor allele frequency (MAF) for each variant was obtained from the ExAC database for the 
global, European and South Asian populations. The functional predicted impact was 
evaluated using SIFT (Kumar et al., 2009), PolyPhen-2 (Adzhubei et al., 2010), 
MutationTaster (Schwarz et al., 2014) and CADD (Kircher et al., 2014) software. ClinVar 
(http://www.ncbi.nlm.nih.gov/clinvar/) was also used in the variants’ classification process. 
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Supplementary Figures and Tables 
 
Figure S1: Plot of the B allele frequencies (BAF) and log R ratios (LRR) values for a 
representative sample from the Turkish cohort visualized with Genome Studio V2011.1.  
The blue dots represent variants incorporated by the HumanOmniExpress BeadChips and 
the red line is the smoothing series for these data. The depicted area (chr19:35234335-
37547219, based on hg19) encompasses TYROBP (identified by the pink vertical line) and 
represents the analysed locus. No large CNVs or large tracts of homozygosity were 
identified. LRR indicates the relative abundance of the genomic DNA around the SNP while 
the BAF of a SNP reflects the relative abundance of B allele intensity. It is an adjusted value 
generated by GenomeStudio, assuming three canonical clusters (A/A: 0.0, A/B: 0.5, B/B: 1).  
 
 
 
	   
 
 
Table S1. Characteristics of the cohort studied. The majority of the cases were diagnosed 
with AD.  
Diagnoses # Cases Male Female Average AAO (SD) 
Mild Cognitive Impairment 20 12 8 66.7 (± 11.6) 
Alzheimer’s Disease 50 15 35 65.9 (± 9.1) 
Frontotemporal Dementia 24 14 10 59.3 (± 14.2) 
*Other 9 7 2 51.1 (±15.9) 
Total 103 48 55 63.2 (±12.3) 
 
*Other includes patients with CADASIL-type dementia, with Lewy Body Disease and with 
Corticobasal Degeneration. # Cases: number of cases, AAO: age-at-onset, SD: standard 
deviation. 
 
 
Table S2. Coding variants identified in the studied cohort of 103 Turkish dementia cases 
(based on hg19). Minor allele frequencies for the studied cohort are presented in column “# 
Cases (MAF)”. Global MAF represents minor allele frequencies for the global population and 
were obtained from the ExAC database. Functional impact classification resulted from the 
prediction obtained with SIFT, PolyPhen-2, MutationTaster and CADD software. All 
predictors classified the p.Val55Leu as benign. MutationTaster and CADD software also 
classified the synonymous variant as a polymorphism. 	  
	  Variant rsID Position Ref Alt # Cases 
(MAF) 
Global MAF ClinVar	   Functional 
Impact 
p.Val55Leu rs77782321 19:36398414 C A 3 
(0.00971)	  
0.01518  Benign/ 
Likely benign 
Benign 
p.Gly41Gly rs111477177 19:36398454 G C 4 
(0.01942)	  
0.02782  Likely benign Benign 
Ref: reference allele, Alt: alternative allele, # Cases: number of cases, MAF: minor allele frequency.	  
	  
	  
